Related Experiment Video
Updated: Mar 8, 2026
04:14
Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution
Published on: April 16, 2019
12.8K
Sodium-Glucose Cotransporter 2 Inhibitors for Metabolic Dysfunction-Associated Steatohepatitis
Jiayang Lin1, Yan Huang2, Bingyan Xu1
1Department of Endocrinology and Metabolism, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Journal of Diabetes
|March 7, 2026
Summary
Metabolic dysfunction-associated steatohepatitis (MASH) improvement requires a significant NAS score decrease or ≤3, with stable fibrosis. MASH resolution involves minimal ballooning and inflammation, alongside no fibrosis worsening.
Area of Science:
- Hepatology
- Gastroenterology
- Metabolic Diseases
Background:
- Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive liver disease.
- Accurate definitions for MASH outcomes are crucial for clinical trials and patient management.
Purpose of the Study:
- To define objective criteria for MASH improvement, resolution, and fibrosis improvement.
- To establish standardized endpoints for MASH clinical studies.
Main Methods:
- Defined MASH improvement based on non-alcoholic fatty liver disease activity score (NAS) changes (≥2-point decrease or NAS ≤3).
- Defined MASH resolution by specific scores for hepatocellular ballooning and lobular inflammation (0 or 0-1, respectively).
- Defined fibrosis improvement by a ≥1 stage reduction, ensuring no MASH component worsening.
Main Results:
- MASH improvement: NAS decrease of ≥2 points or NAS ≤3 at 48 weeks, without fibrosis worsening.
- MASH resolution: Ballooning score of 0 and inflammation score of 0 or 1 at 48 weeks, without fibrosis worsening.
- Fibrosis improvement: ≥1 stage reduction at 48 weeks, without MASH component worsening.
Conclusions:
- Established clear, quantifiable definitions for MASH improvement, resolution, and fibrosis improvement.
- These definitions provide standardized endpoints for evaluating MASH therapies.
- Consistent outcome measures are vital for advancing MASH research and treatment.
Related Concept Videos
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
769
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
769
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
713
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
713
01:27Glucose Transporters
27.8K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
27.8K
01:24Glucagon-like Receptor Agonists
1.1K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.1K
01:23Dipeptidyl Peptidase 4 Inhibitors
821
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
821
01:26Glucose Absorption Into the Small Intestine
36.7K
Complex carbohydrates consumed cannot be absorbed into the small intestine in their original form. First, they must be hydrolyzed to a monosaccharide form such as glucose or galactose. These monosaccharides are then transported across the intestinal membrane and into the blood via transcellular transport. The intestinal epithelial cells allow the movement of these monosaccharides with a defined 'entry' through membrane transporter proteins present on their apical membrane and...
36.7K